🔗 Share this article

As America undertakes unprecedented changes to its immunization schedules, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccinations during the pandemic and has concentrated on possible fatalities following COVID-19 immunization in her brief tenure at the FDA.

Proposed Overhauls to Childhood Vaccine Schedule

Health officials planned to announce sweeping revisions to the childhood vaccine schedule earlier this month, synchronizing the US with the Danish immunization schedule, sources say – a major change that would place the US out of alignment with many the world with no evidence for benefit. The announcement has been pushed back until the coming year.

Rather than the director of the vaccine center, Høeg is scheduled to speak at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this calendar year.

Consolidating Power at the Regulatory Body

This interim role could signify a strengthened alliance between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad solidify control at the agency – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

The new acting director has often pushed for ending specific childhood immunization guidelines in the US in order to be more like Denmark, a nation with universal health coverage and a population approximately the population of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccination policy – traditionally the domain of Prasad, head of the FDA’s CBER – instead of drug regulation.

Concerns Over Qualifications

Høeg has little discernible background in pharmaceutical research, regulation or management, which has been typical for previous directors of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for overseeing the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in running a major agency. She lacks background in industry regulation.”

Past heads of the center would “understand legal statutes and the science of pharmaceutical innovation”, commented a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that previous people who led CBER have had.”

The drug center has an immense portfolio at the FDA, Woodcock stated.

“The public just focuses on the innovative therapies, but the off-patent medication office authorizes numerous generic drugs. There’s a biosimilars division, non-prescription drug unit and more, and every single one need to be supervised,” Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant leadership element to the role, which oversees more than 5,000 staff members. “It is a massive leadership role, if you execute it properly,” the former official said.

Response and Controversial Programs

When asked about questions about Høeg’s fitness for the role and whether this assignment represents increased cooperation among regulatory chiefs on immunizations, a press secretary said that the “questions stem from flawed premises”.

“Her experience matches the duties of her position,” the official said, pointing to the time Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's new priority voucher program, a disputed one-day therapy clearance system that allegedly worried her preceding directors. “How are these therapies being picked for this expedited pathway? Who is making the choices?” Howard said. “There is a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he stated, “the Food and Drug Administration seems to be moving towards less stringent oversight of all drugs, aside from vaccines.”

Documented Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a more established, if concerning, past, some experts have noted. She published a study using unconfirmed public submissions to determine the frequency of myocarditis following Covid vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccines are pose a greater threat than they are.

Among her “desired changes” for the new government encompassed revising rules for novel immunizations and ending “optional” immunizations, she stated after the election on a podcast. At the agency, Høeg has allegedly floated the idea of preventing teenage boys from getting Covid vaccines.

“She’s an complete dogmatist who begins with her beliefs and tailors the evidence to accommodate the science in a extremely disingenuous, untruthful fashion,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg joined other contrarians, {like|